Treatment of 4T1 tumors with AR-R17779 alone led to a reduction in tumor growth compared with treatment with AR-R17779 + anti-CD8 antibody (Fig. 8D), anti-CD8 antibody alone (Fig. 8E), and vehicle with isotype (Fig. 8F). This evidence concerns the gene CD8A and neoplasm.